


RECEIVED

AUG 20 2002

TECH CENTER 1600/2900



A-527.ST25.txt  
SEQUENCE LISTING

<110> FEIGE, ULRICH  
LIU, CHUAN-FA  
CHEETHAM, JANET C.  
BOONE, THOMAS CHARLES

2 <120> MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

D <130> A-527

<140> 09/428,082  
<141> 1999-10-22

<150> 60/105,371  
<151> 1998-10-23

<160> 1133

<170> PatentIn version 3.1

<210> 1  
<211> 684  
<212> DNA  
<213> HUMAN

<220>  
<221> CDS  
<222> (1)..(684)  
<223>

<400> 1  
atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc ctg 48  
Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu  
1 5 10 15

ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc 96  
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
20 25 30

atg atc tcc ccg acc cct gag gtc aca tgc gtg gtg gac gtg agc 144  
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
35 40 45

cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag 192  
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu  
50 55 60

gtg cat aat gcc aag aca aag ccg ccg gag gag cag tac aac agc acg 240  
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr  
65 70 75 80

tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat 288  
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
85 90 95

ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc 336  
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro  
100 105 110

atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag 384  
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
115 120 125

gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc 432  
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val  
130 135 140

139

D

## A-527.ST25.txt

agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val	480
145 150 155 160	
gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro	528
165 170 175	
ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr	576
180 185 190	
gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val	624
195 200 205	
atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu	672
210 215 220	
tct ccg ggt aaa Ser Pro Gly Lys	684
225	

<210> 2  
<211> 228  
<212> PRT  
<213> HUMAN

<400> 2

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu  
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu  
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr  
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro  
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val  
130 135 140